Ghent University Academic Bibliography

Your filters: cql: author="Lugaresi, Alessandra" or (type any "bookEditor issueEditor" and editor="Lugaresi, Alessan...

Add to list
Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis

Yi Chao Foong, Daniel Merlo, Melissa Gresle, Katherine Buzzard, Dana Horakova, Eva Kubala Havrdova, Tomas Kalincik, Izanne Roos, Suzanne Hodgkinson, Jeannette Lechner-Scott, et al.

(2026) JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 97(1). p.50-58
Add to list
Effect of late-onset on multiple sclerosis phenotype and outcome : evidence from a multi-national registry

Amira Souissi, Francesco Patti, Tim Spelman, Clara Chisari, Amina Gargouri, Nevin John, Allan G. Kermode, Tomas Kalincik, Helmut Butzkueven, Seyed Aidin Sajedi, et al.

(2026) JOURNAL OF NEUROLOGY. 273(2).
Add to list
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years

Jodie I Roberts, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Serkan Ozakbas, Alessandra Lugaresi, Valentina Tomassini, Raed Alroughani, Katherine Buzzard, Olga Skibina, et al.

(2025) JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 96(12). p.1185-1193
Add to list
Explainable time-to-progression predictions in multiple sclerosis

Robbe D’hondt, Klest Dedja, Sofie Aerts, Bart Van Wijmeersch, Tomas Kalincik, Stephen Reddel, Eva Kubala Havrdova, Alessandra Lugaresi, Bianca Weinstock-Guttman, Saloua Mrabet, et al.

(2025) COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE. 263.
Add to list
- Journal Article
- A2
- open access
Persistent progression independent of relapse activity in multiple sclerosis

Chao Zhu, Zhen Zhou, Tomas Kalincik, Izanne Roos, Katherine Buzzard, Olga Skibina, Raed Alroughani, Jens Kuhle, Marc Girard, Pierre Grammond, et al.

(2025) BRAIN COMMUNICATIONS. 7(5).
Add to list
- Journal Article
- A1
- open access
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Simona Toscano, Tim Spelman, Serkan Ozakbas, Raed Alroughani, Clara G. Chisari, Salvatore Lo Fermo, Alexandre Prat, Marc Girard, Pierre Duquette, Guillermo Izquierdo, et al.

(2025) NEUROTHERAPEUTICS. 22(2).
Add to list
- Journal Article
- A1
- open access
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

Ashkan Pirmani, Edward De Brouwer, Ádám Arany, Martijn Oldenhof, Antoine Passemiers, Axel Faes, Tomas Kalincik, Serkan Ozakbas, Riadh Gouider, Barbara Willekens, et al.

(2025) NPJ DIGITAL MEDICINE. 8(1).
Add to list
Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis

Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Dana Horakova, Bianca Weinstock-Guttman, Vahid Shaygannejad, Masoud Etemadifar, Raed Alroughani, et al.

(2025) JAMA NEUROLOGY. 82(6). p.614-625
Add to list
- Journal Article
- A1
- open access
Pregnancy-related disease outcomes in women with moderate to severe multiple sclerosis disability

Jessica Shipley, Heidi N. Beadnall, Paul G. Sanfilippo, Wei Zhen Yeh, Dana Horakova, Eva Kubala Havrdova, Pavel Hradilek, Tomas Kalincik, Izanne Roos, Alexandre Prat, et al.

(2025) JAMA NETWORK OPEN. 8(9).
Add to list
Routine CSF parameters as predictors of disease course in multiple sclerosis : an MSBase cohort study

Cathérine Dekeyser (UGent) , Matthias Hautekeete, Melissa Cambron, Vincent Van Pesch, Francesco Patti, Jens Kuhle, Samia Khoury, Jeanette Lechner Scott, Oliver Gerlach, Alessandra Lugaresi, et al.

(2024) JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 95(11). p.1021-1031

Academic Bibliography

Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis

Effect of late-onset on multiple sclerosis phenotype and outcome : evidence from a multi-national registry

Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years

Explainable time-to-progression predictions in multiple sclerosis

Persistent progression independent of relapse activity in multiple sclerosis

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis

Pregnancy-related disease outcomes in women with moderate to severe multiple sclerosis disability

Routine CSF parameters as predictors of disease course in multiple sclerosis : an MSBase cohort study

Contents

Support

Contact